Transdermal Delivery of Antihypertensive Agents: A tabular update

Transdermal Drug Delivery System is viable drug delivery platform technology and has a strong market world wide. Transdermal Drug Delivery System is particularly desirable for drugs that need prolonged administration at controlled plasma level that basis make appropriateness to antihypertensive agents for their transdermal development. Controlled zero order absorption, easily termination of drug delivery, easy to administration also support for popularity of transdermal delivery. This paper reviews the work on transdermal studies of antihypertensive agents in the tabular form.Keywords: Transdermal, Antihypertensive agents

Transdermal Spray in Hormone Delivery

This review examines advances in hormone delivery, particularly using transdermal spray. Transdermal gels, emulsions, patches, subcutaneous implants and sprays have been developed for transdermal hormone therapy in recent years. Transdermal sprays, in their general form of metered-dose transdermal spray, possess major advantages such as enhanced passive transdermal drug delivery with little or no skin irritations, improved cosmetic acceptability, dose flexibility, uniform distribution on the application site and ease of manufacture, and have thus assumed significant importance in hormone delivery. Estradiol, nestrone, testosterone and hydrocortisone aceponate are some of the drugs prepared as metered-dose transdermal spray. Results from recent surveys indicate that there is a market for the delivery system and ongoing development of transdermal sprays for hormone delivery.Keywords: Transdermal, Delivery systems, Metered dose, Spray, Hormon

Recent advancement in the method of transdermal drug delivery system: A review

A transdermal patch is a medicated adhesive patch that is applied to the skin and used to deliver a particular amount of medication into the bloodstream through the skin. It aids in the recovery of an injured bodily part. The transdermal drug delivery system (TDDS) provides an alternative safe means of drug delivery to previous intrusive techniques. In the past, topically applied lotions and ointments were the most commonly utilised systems for dermatological issues. The fact that some of these formulations cause systemic side effects indicates that they are absorbed through the skin. All topically applied medication formulations intended to transport the active ingredient into the general circulation are included in the transdermal delivery system. To overcome the skin's formidable barrier to topical medication administration, several substances have been utilised. Because of their unique qualities, such as improved bioavailability, regulated pharmaceutical release, and improved patient compliance, TDDS have recently gained increased attention. The current review focuses on the various advancements in transdermal drug delivery, as well as the various available methods for preparing transdermal patches, characterization and assessment tools for transdermal patch preparation, patents, transdermal compound clinical trials, and drug approved and future applications of transdermal drug delivery systems. As a result, in recent years, the Transdermal Drug Delivery System has received a lot of attention

Evaluation of Microparticulate Ovarian Cancer Vaccine via Transdermal Route of Delivery

Ovarian cancer is the fifth most commonly occurring malignancy in women, with the highest mortality rate among all the gynecological tumors. Microparticulate vaccine can serve as an immunotherapeutic approach with a promising antigenic delivery system without a need for conventional adjuvants. In this study, a microparticulate vaccine using whole cell lysate of a murine ovarian cancer cell line, ID8 was prepared by spray drying. Further, the effect of interleukins (ILs) such as IL-2 and IL-12 was evaluated in a separate study group by administering them with vaccine particles to enhance the immune response. The vaccine microparticles were administered to C57BL/6 female mice via transdermal alone and in combination with the oral route. The transdermal vaccine was delivered using a metallic microneedle device, AdminPen™. Orally administered microparticles also included an M-cell targeting ligand, Aleuria aurantia lectin, to enhance the targeted uptake from microfold cells (M-cells) in Peyer\u27s patches of small intestine. In case of combination of routes, mice were given 5 transdermal doses and 5 oral doses administered alternatively, beginning with transdermal dose. At the end of vaccination, mice were challenged with live tumor cells. Vaccine alone resulted in around 1.5 times tumor suppression in case of transdermal and combination of routes at the end of 15th week when compared to controls. Inclusion of interleukins resulted in 3 times tumor suppression when administered with transdermal vaccine and around 9 times tumor suppression for the combination route of delivery in comparison to controls. These results were further potentiated by serum IgG, IgG1 and IgG2a titers. Moreover, CD8+ T-cell, CD4+ T-cell and NK (natural killer) cell populations in splenocytes were elevated in case of vaccinated mice. Thus, vaccine microparticles could trigger humoral as well as cellular immune response when administered transdermally and via combination of route of delivery. However overall, vaccine administered with interleukins, via combination of route, was found to be the most efficacious to suppress the tumor growth and lead to a protective immune response

Advances and development in transdermal drug delivery system-A review

It is one of the best pharmaceutical dosage forms for those patients, they cannot take medicaments orally. Transdermal drug delivery system (TDDS) established itself as an integral part of novel drug delivery systems (NDDS). On the application of Transdermal patches, the delivery of the drug across dermis gives the systemic effect. TDDS is costly alternative to conventional formulation. It is also important due to its unique advantage. Controlled absorption, more uniform plasma levels, improved bioavailability, reduced side effects, painless and simple application and flexibility of terminating drug administration by simply removing the patch from the skin are some of the potential advantages of transdermal drug delivery. Development of controlled release transdermal dosage form is a complex process involving extensive efforts. This review article describes the methods of preparation of different types of transdermal patches. In addition, the various methods of evaluation of transdermal dosage form and Advance Development in TDDS have also been reviewed

Nanoemulsion as potential vehicles for transdermal delivery of pure phytopharmaceuticals and poorly soluble drug

Nanoemulsion (NE) is defined as an O/W or W/O emulsion producing a transparent product that has a droplet size from 20-200nm and does not have the tendency to coalesce. It is promising for transdermal delivery of drugs as an efficient route of drug administration. Several mechanisms have been proposed to explain the advantages of nanoemulsions for the transdermal delivery of drugs. In transdermal delivery, the goal of dosage design is to maximize the flux through the skin into systemic circulation. A useful strategy for improving percutaneous flux is to improve the concentration of drug or choose an appropriate vehicle for the transdermal delivery. The nanoemulsions system should be a promising vehicle due to powerful ability to deliver drug through skins. With these approaches, the aim of this present study is to review the potential of nanoemulsion formulation for transdermal delivery of pure phytopharmaceuticals and poorly soluble drugs. Some nanoemulsions have however exhibited sufficiently high level of stability for them to be proposed as vehicle for drug delivery. Using the transdermal route eliminates the side effects, increases patient compliance, avoids first-pass metabolism, enhance bioavailability and maintains the plasma drug level for a longer period of time.Keywords: Transdernmal, poorly soluble drug, phytopharmaceuticals, nanoemulsion

A 3D-printed microfluidic-enabled hollow microneedle architecture for transdermal drug delivery.

Embedding microfluidic architectures with microneedles enables fluid management capabilities that present new degrees of freedom for transdermal drug delivery. To this end, fabrication schemes that can simultaneously create and integrate complex millimeter/centimeter-long microfluidic structures and micrometer-scale microneedle features are necessary. Accordingly, three-dimensional (3D) printing techniques are suitable candidates because they allow the rapid realization of customizable yet intricate microfluidic and microneedle features. However, previously reported 3D-printing approaches utilized costly instrumentation that lacked the desired versatility to print both features in a single step and the throughput to render components within distinct length-scales. Here, for the first time in literature, we devise a fabrication scheme to create hollow microneedles interfaced with microfluidic structures in a single step. Our method utilizes stereolithography 3D-printing and pushes its boundaries (achieving print resolutions below the full width half maximum laser spot size resolution) to create complex architectures with lower cost and higher print speed and throughput than previously reported methods. To demonstrate a potential application, a microfluidic-enabled microneedle architecture was printed to render hydrodynamic mixing and transdermal drug delivery within a single device. The presented architectures can be adopted in future biomedical devices to facilitate new modes of operations for transdermal drug delivery applications such as combinational therapy for preclinical testing of biologic treatments

Recent Advancement on TDDS (Transdermal Drug Delivery System)

The creation of a transdermal drug delivery system (TDDS) has been one of the most sophisticated and innovative approaches to drug delivery. The transdermal drug delivery system has attracted considerable attention because of its many potential advantages, including better patient compliance, avoidance of gastrointestinal disturbances, hepatic first-pass metabolism, and sustained delivery of drugs to provide steady plasma profiles, particularly for drugs with short half-lives, reduction in systemic side effects and enhanced therapeutic efficacy. This review article covers a brief outline of the transdermal drug delivery system; Highlight the restrictions, drawbacks, shortcomings, and Versatile benefits of delivery systems

Poly(lactic-co-glycolic) acid drug delivery systems through transdermal pathway : an overview

In past few decades, scientists have made tremendous advancement in the field of drug delivery systems (DDS), through transdermal pathway, as the skin represents a ready and large surface area for delivering drugs. Efforts are in progress to design efficient transdermal DDS that support sustained drug release at the targeted area for longer duration in the recommended therapeutic window without producing side-effects. Poly(lactic-co-glycolic acid) (PLGA) is one of the most promising Food and Drug Administration approved synthetic polymers in designing versatile drug delivery carriers for different drug administration routes, including transdermal drug delivery. The present review provides a brief introduction over the transdermal drug delivery and PLGA as a material in context to its role in designing drug delivery vehicles. Attempts are made to compile literatures over PLGA-based drug delivery vehicles, including microneedles, nanoparticles, and nanofibers and their role in transdermal drug delivery of different therapeutic agents. Different nanostructure evaluation techniques with their working principles are briefly explained.RL thanks the funding support from Singapore National Research Foundation under its Translational and Clinical Research Flagship Programme (NMRC/TCR/008-SERI/2013) and administered by the Singapore Ministry of Health’s National Medical Research Council and Co-operative Basic Research Grant from the Singapore National Medical Research Council (Project No. NMRC/CBRG/0048/2013).info:eu-repo/semantics/publishedVersio

Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery

AbstractThe aim of this work is to investigate penetration enhancers in proniosomes as a transdermal delivery system for nisoldipine. This was performed with the goal of optimising the composition of proniosomes as transdermal drug delivery systems. Plain proniosomes comprising sorbitan monostearate, cholesterol, ethanol and a small quantity of water were initially prepared. Subsequently, proniosomes containing lecithin or skin penetration enhancers were prepared and evaluated for transdermal delivery of nisoldipine. The plain proniosomes significantly enhanced the transdermal flux of nisoldipine to reach 12.18μgcm−2h−1 compared with a saturated aqueous drug solution which delivered the drug at a rate of 0.46μgcm−2h−1. Incorporation of lecithin into such proniosomes increased the drug flux to reach a value of 28.51μgcm−2h−1. This increase can be attributed to the penetration enhancing effect of lecithin fatty acid components. Replacing lecithin oleic acid (OA) produced proniosomes of comparable efficacy to the lecithin containing system. The transdermal drug flux increased further after incorporation of propylene glycol into the OA based proniosomes. Similarly, incorporation of isopropyl myristate into plain proniosomes increased drug flux. The study introduced enhanced proniosomes as a promising transdermal delivery carrier and highlighted the role of penetration enhancing mechanisms in enhanced proniosomal skin delivery. The study opened the way for another line of optimisation of niosome proconcentrates